Patent · US Active

Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases

US8309608B2 · kind B2 · utility

0Cited by

8References

8Claims

0Family size

Assignee

Sanofi-Aventis Deutschland GMBH · DE

Inventors

Andreas M. Zeiher · Glückstadt, DE
Stefanie Dimmeler · Frankfurt am Main, DE
Christopher Heeschen · Frankfurt am Main, DE
Hartmut Ruetten · Ingelheim am Rhein, DE

Key dates

Filing date	Nov 2, 2004
Grant date	Nov 13, 2012
Priority date	—
Expiry date	Oct 2, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/54
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the use of compounds which enhance the transcription of endothelial nitric oxide synthase (eNOS) for treating stem and progenitor cells in the cell therapy of patients with ischemic heart diseases such as coronary heart disease or ischemic cardiomyopathy. Treatment of such cells which are isolated from bone marrow, for example, with an eNOS transcription enhancer prior to their administration improves their functional activity and ameliorates neovascularization of the heart and cardiac regeneration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.